CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Campath-1Hdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00365846
NCT00365846Phase 2Completed
CompareCT.gov

"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation

University of Wisconsin, Madison·interventional·Posted Aug 18, 2006·Updated Oct 3, 2012

In Brief

A Phase 2 clinical trial evaluating Campath-1H for Renal Transplant. Completed, enrolled 29 participants across 1 site.

Detailed Summary

The purpose of the study is to see if campath-1H can be used in first time renal transplant subjects to prevent rejection and reduce the overall amount of anti-rejection medications that patients take on a daily basis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplant
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 18, 2006
Enrollment StartAug 1, 2000
Primary CompletionJul 1, 2005
Study CompletionJul 1, 2006
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 19.9 years ago

Interventions

Campath-1Hdrug